Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5625

1.

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.

Sutera PA, Bernard ME, Wang H, Heron DE.

Front Oncol. 2018 Jul 27;8:282. doi: 10.3389/fonc.2018.00282. eCollection 2018.

2.

Prognostic significance of neutrophil/prealbumin ratio for intrahepatic cholangiocarcinoma undergoing curative resection.

Huang XT, Huang CS, Li JH, Cai JP, Chen W, Yin XY.

HPB (Oxford). 2018 Aug 2. pii: S1365-182X(18)32673-X. doi: 10.1016/j.hpb.2018.06.1810. [Epub ahead of print]

PMID:
30078755
3.

Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy.

Liu X, Wu Z, Lin E, Li W, Chen Y, Sun X, Zhou Z.

Clin Nutr. 2018 Jul 23. pii: S0261-5614(18)31217-2. doi: 10.1016/j.clnu.2018.07.015. [Epub ahead of print]

PMID:
30075998
4.

Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).

Mizusawa J, Fukutomi A, Katayama H, Ishii H, Ioka T, Okusaka T, Ueno H, Ueno M, Ikeda M, Mizuno N, Ozaka M, Fukuda H, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group.

Pancreatology. 2018 Jul 27. pii: S1424-3903(18)30634-3. doi: 10.1016/j.pan.2018.07.007. [Epub ahead of print]

PMID:
30075908
5.

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer.

Peng J, Ou Q, Pan Z, Zhang R, Zhao Y, Deng Y, Lu Z, Zhang L, Li C, Zhou Y, Guo J, Wan D, Fang Y.

Aging (Albany NY). 2018 Aug 2. doi: 10.18632/aging.101512. [Epub ahead of print]

6.

Comparison of Platelet Distribution Width and CA19-9 in Resectable Pancreas Cancer.

Ulutas KT, Sarici IS, Arpaci A.

Med Arch. 2018 Jun;72(3):210-213. doi: 10.5455/medarh.2018.72.210-213.

7.

A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma.

Yang SH, Shao YY, Lin CC, Kuo SH, Cheng AL, Yeh KH.

Anticancer Res. 2018 Aug;38(8):4805-4812. doi: 10.21873/anticanres.12790.

PMID:
30061252
8.

Serum chemokine CXCL-8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR-2, CRP and classical tumor markers (CA 19-9 and CEA).

Litman-Zawadzka A, Łukaszewicz-Zając M, Gryko M, Kulczyńska-Przybik A, Mroczko B.

Pol Arch Intern Med. 2018 Jul 27. doi: 10.20452/pamw.4307. [Epub ahead of print]

9.

Carbohydrate Antigen 19-9 Level in Patients with Autosomal Dominant Polycystic Kidney Disease.

Fliszkiewicz M, Niemczyk M, Kulesza A, Pączek L.

Transplant Proc. 2018 Jul - Aug;50(6):1631-1633. doi: 10.1016/j.transproceed.2018.04.052. Epub 2018 May 1.

PMID:
30056872
10.

Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.

Omiya Y, Ichikawa S, Satoh Y, Motosugi U, Nakajima N, Onishi H.

Abdom Radiol (NY). 2018 Jul 25. doi: 10.1007/s00261-018-1647-4. [Epub ahead of print]

PMID:
30043215
11.

Angiogenic miRNAs, the angiopoietin axis and related TIE2-expressing monocytes affect outcomes in cholangiocarcinoma.

Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Katou S, Schierle K, Robson SC, Splith K, Wiltberger G, Reutzel-Selke A, Jonas S, Pascher A, Bahra M, Pratschke J, Schmelzle M.

Oncotarget. 2018 Jul 6;9(52):29921-29933. doi: 10.18632/oncotarget.25699. eCollection 2018 Jul 6.

12.

[Resection of a Granulocyte Colony-Stimulating Factor-Producing Anaplastic Carcinoma of the Pancreas, Associated with Humoral Hypercalcemia of Malignancy].

Seki H, Yasui N, Shimada A, Matsumoto H, Domoto H.

Gan To Kagaku Ryoho. 2018 May;45(5):859-862. Review. Japanese.

PMID:
30026452
13.

Immunosensor for Pancreatic Cancer Based on Electrospun Nanofibers Coated with Carbon Nanotubes or Gold Nanoparticles.

Soares JC, Iwaki LEO, Soares AC, Rodrigues VC, Melendez ME, Fregnani JHTG, Reis RM, Carvalho AL, Corrêa DS, Oliveira ON Jr.

ACS Omega. 2017 Oct 31;2(10):6975-6983. doi: 10.1021/acsomega.7b01029. Epub 2017 Oct 19.

14.
15.

Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at 18F-FDG-PET/CT: prognostic implication of metabolic parameters and tumor markers.

Sabaté-Llobera A, Gràcia-Sánchez L, Reynés-Llompart G, Ramos E, Lladó L, Robles J, Serrano T, Mestres-Martí J, Gámez-Cenzano C.

Clin Transl Oncol. 2018 Jul 18. doi: 10.1007/s12094-018-1926-0. [Epub ahead of print]

PMID:
30022384
16.

Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer.

Pombeiro I, Loosen SH, Roy S, Schueller F, Niewenhuisen L, Luedde M, Vucur M, Tacke F, Binnebösel M, Schoening W, Trautwein C, Luedde T, Neumann UP, Roderburg C.

J Clin Med. 2018 Jul 13;7(7). pii: E175. doi: 10.3390/jcm7070175.

17.

Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.

Yang W, Luo Y, Hu S, Li Y, Liu Q.

Oncol Lett. 2018 Aug;16(2):1551-1556. doi: 10.3892/ol.2018.8792. Epub 2018 May 24.

18.

Ultrasound/CT combined with serum CEA/CA19.9 in the diagnosis and prognosis of rectal cancer.

Zhang B, Sun Z, Song M, Ma S, Tian Y, Kong Q.

J BUON. 2018 May-Jun;23(3):592-597.

PMID:
30003724
19.

Rare case of a gallbladder neuroendocrine carcinoma.

Fujii M, Saito H, Shiode J.

Clin J Gastroenterol. 2018 Jul 12. doi: 10.1007/s12328-018-0883-z. [Epub ahead of print]

PMID:
30003469
20.

Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?

Ito M, Oshima Y, Yajima S, Suzuki T, Nanami T, Shiratori F, Funahashi K, Nemoto T, Shimada H.

Ann Gastroenterol Surg. 2018 Jun 5;2(4):313-318. doi: 10.1002/ags3.12175. eCollection 2018 Jul.

Supplemental Content

Loading ...
Support Center